41. Arch Dermatol -- Page Not Found Induction of Hyperacute graftvs-host disease After Donor Leukocyte Infusions AuthorInformation Jesús Fernández-Herrera, MD, PhD; Ruud Valks, MD; Carlos Feal http://archderm.ama-assn.org/issues/v135n3/abs/dob8030.html

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery MSJAMA Science News Updates Meetings Peer Review Congress The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"

42. BONE MARROW TRANSPLANTS: Graft Vs. Host Disease BONE MARROW TRANSPLANTS graft vs. host disease People with diseasessuch as leukemia, lymphoma or Hodgkin's disease may need a http://www.itvisus.com/broadcast/medical/bone_marrow_trans_2/

BONE MARROW TRANSPLANTS: Graft vs. Host Disease People with diseases such as leukemia, lymphoma or Hodgkin's Disease may need a bone marrow transplant to survive. These transplants save lives, but they can be accompanied by several risk factors. Click here to view air times. Click here to learn more. Click here to return to currently airing. Click here to view the press release.

43. Press Release - Graft Vs. Host Disease PRESS RELEASE. Understanding BONE MARROW TRANSPLANTS graft vs. HostDisease. People with diseases such as leukemia, lymphoma or Hodgkin http://www.itvisus.com/broadcast/medical/press_release/pr_bonetrans.htm

PRESS RELEASE Understanding BONE MARROW TRANSPLANTS: Graft vs. Host Disease People with diseases such as leukemia, lymphoma or Hodgkin’s Disease may need a bone marrow transplant to survive. These transplants save lives, but they can be accompanied by several risk factors. The patient’s immune system may reject the transplant. Also, the donor’s cells may attack the patient’s organs and tissues; this is called Graft-versus-host Disease (GvHD) and it can be a major complication of bone marrow transplants. The closer the match between the donor’s and patient’s tissue type, the less likely it is that rejection or GvHD will occur. This program carefully explains the procedure of bone marrow transplantation, the importance of clinical trials and what is being done to combat GvHD with newly developed pharmaceuticals. BONE MARROW TRANSPLANTS: Graft vs. Host Disease

44. Comprehensive Transplant Center - Johns Hopkins Medical Institutions Volume 1, Number 1 graft vs. host disease, The TwoEdged Sword. Researchersfrom the Oncology Center at Johns Hopkins Medical Center http://www.hopkinsmedicine.org/transplant/newsletter/11/10.html

Volume 1, Number 1 Graft vs. Host Disease, The Two-Edged Sword Researchers from the Oncology Center at Johns Hopkins Medical Center have developed a way to boost the immune system and reduce the rate of tumor recurrence in both allogenic (donor) and autologous (self-donor) transplants by using Hopkins-developed techniques to induce a mild form of graft versus host disease (GVHD). Severe GVHD is a life-threatening complication of donor marrow transplantation. The condition occurs when a type of immune system cell (T-cells) from the donor marrow attack tissue and organs (including tumor cells) in the new host. In allogenic transplants, Center scientists are using special techniques to remove most of the T-cells from donor marrow prior to transplantation. This markedly decreases the risk of life-threatening GVHD while still allowing T-cells to fight tumors. Viki Altomonte, R.N., B.S.N., nurse coordinator of the GVHD Clinic said, "With the donor transplants, we want to minimize GVHD without totally eliminating the graft vs. tumor (GVT) effect. The problem with donor grafts is that if we too aggressively eliminate that response, we also eliminate GVT, and patients may relapse. We're walking a very fine line." To combat GVHD, she said, "we use elutriationa T-cell depletion technique that decreases the number of T-cells that cause GVHDbut we don't totally eliminate it, thus decreasing the risk of relapse."

45. Nature Publishing Group Tools and Procedures. graftvs-leukemia activity and graft-vs-host diseaseinduced by allogeneic Th1- and Th2-type CD4 + T cells in mice. http://www.nature.com/cgi-taf/DynaPage.taf?file=/thj/journal/v2/n2/full/6200087a

46. Nature Publishing Group PubMed ; Korngold, R. Sprent, J. Tcell subsets in graft-vs. -host disease.in graft-vs.-host disease Immunology, Pathophysiology, and Treatment (eds. http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v8/n6/full/nm0602-57

47. XENOGENEIC HUMORAL GRAFT-VS-HOST DISEASE FOLLOWING HAMSTER TO RAT BONE MARROW TR 1004. XENOGENEIC HUMORAL graftvs-host disease FOLLOWING HAMSTER TORAT BONE MARROW TRANSPLANTATION. We have reported that xenogeneic http://www.a-s-t.org/abstracts99/1005.htm

XENOGENEIC HUMORAL GRAFT-VS-HOST DISEASE FOLLOWING HAMSTER TO RAT BONE MARROW TRANSPLANTATION We have reported that xenogeneic chimeras can be created in rats by bone mrrow transplantation (BMTx) from hamsters. However, all recipients with successful engraftment succumbed to GVHD, which can he either cellular and/or humoral in origin. LEW rats underwent splenectomy (Spx) on day -7 and TBI of 10 Gy 3 d before BMTx. 300x10 Gp Immunosuppression n Recipient Survival (d) Cellular GVHD Humoral GVHD Max Median Min none FK* (7d) FK* (30d) * FK: tacrolimus 1 mg/ kg/ day, I.M. T Miki, Y-H Lee, A Tandin, AL Goller, V Subbotin. R Kuddus, AS Rao, JJ Fung, TE Starzl, LA Valdivia. Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center. Pittsburgh, PA.

48. Alphamusic - Leider Keine Treffer Gefunden Translate this page Donnerstag, den 06. Februar 2003. graft-vs.-host disease (Rev and Expanded) BuchHarperCollins Publishers, 0002 Bestell-Nr. 0-8247-9728-0 251.62 EUR. 824. http://www.alphamusic-online.de/280/0824797280.html

Sehr geehrter Kunde, unsere Produktdatenbank wird derzeit aktualisiert. Daher können wir Ihnen im Augenblick nicht das von Ihnen gesuchte Original-Produkt anzeigen, sondern stellen Ihnen interessante Auktionen zu Ihrem Suchbegriff vor. Melden Sie sich jetzt bei Ebay an und bieten Sie für diese interessanten Produkte mit. Ihr Alphamusic-Team Leider keine Treffer gefunden. Ausschlussklausel

49. Arch Otolaryngol Head Neck Surg -- Page Not Found graftvs-host disease as a Cause of Enlargement of the Epiglottis in an ImmunocompromisedChild Author Information Juan I. de Diego, MD; Maria P. Prim, MD http://archotol.ama-assn.org/issues/v127n4/abs/ocn00590.html

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery MSJAMA Science News Updates Meetings Peer Review Congress The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"

50. UASOM Main Digital Library graft vs. host disease Patient/Family Resources. See also General HematologyPatient/Family Resources; graft vs. host disease Clinical Resources. http://uasom-dl.slis.ua.edu/patientinfo/dermatology/immunedisorders/grafthostdis

Patient/Family Resources by Topic: Hematology Graft vs. Host Disease Patient/Family Resources Spanish Miscellaneous See also: General Hematology Patient/Family Resources Graft vs. Host Disease Clinical Resources MEDLINE plus Medical Encyclopedia: Table of contents Graft-versus-Host Disease: English Spanish Spanish MEDLINE plus Medical Encyclopedia: Table of contents Graft-versus-Host Disease: English Spanish Miscellaneous Graft vs. Host Disease Patient/Family Resources YAHOO - Health:Medicine:Hematology Additional Hematology resources ( These sites have not been reviewed. Lister Hill Library of the Health Sciences University of Alabama at Birmingham Service provided by the Clinical Digital Libraries Project of the UA and UNT Schools of Library and Information Studies Powered by UA Digital Libraries Navigation Lab technology

51. Medicine Branch - Graft Vs. Host Disease Protocols graft vs. host disease Protocols The protocols for this category are listedbelow. Click anywhere in a linked title to view a protocol's http://www-dcs.nci.nih.gov/branches/medicine/protocols/gvhd.html

Graft vs. Host Disease Protocols The protocols for this category are listed below. Click anywhere in a linked title to view a protocol's write-up on Cancernet.gov (Please note that you will leave the Medicine Branch website). E-mail a protocol's point of contact by clicking the linked name. 99-C-0143 - Phase I Randomized Pilot Study of Donor Th2 Cells for Prevention of Graft Versus Host Disease Following Non-Myeloablative, HLA Matched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies Principal Investigator: Dr. Daniel Fowler Point of Contact: © 2000-2001 Center for Cancer Research at the National Cancer Institute. Maintained by clarkph@mail.nih.gov for the CCR. Last Updated: March 26, 2001 DCS Home Clinical Trials DCS Research News and Events ... NIH Home Page

52. Graft-Versus-Host Disease Sclerodermoid phase, Localized or generalized lesions. Sclerodermatousgraftvs-host disease clinical and pathological study of 17 patients. http://www.thedoctorsdoctor.com/diseases/graft_vs_host_disease.htm

Background Graft-versus-host disease (GVH) is a disease of modern medicine. It most commonly occurs in bone marrow transplant patients receiving an allogeneic transplant of immunocompetent lymphocytes. The donor cytotoxic T lymphocytes attack the recipient's organs including skin, gut, liver, and mucous membranes. It may occur in 50% of recipients of allogeneic bone marrow transplants. GVH may also occur after maternofetal blood transfusions, intrauterine exchange transfusions, and administration of non-irradiated blood products to patients with metastatic malignancies or with immunodeficiencies. OUTLINE Epidemiology Pathogenesis Gross Appearance and Clinical Variants Histopathological Features and Variants ... Internet Links EPIDEMIOLOGY CHARACTERIZATION SYNONYMS GVH PATHOGENESIS CHARACTERIZATION METALLOPROTEINASES Overexpression of Tissue Inhibitor of Metalloproteinases-3 in Intestinal and Cutaneous Lesions of Graft-versus-Host Disease. Salmela MT, Karjalainen-Lindsberg ML, Jeskanen L, Saarialho-Kere U.

53. Lichenoid Dermatoses disease (PLEVA). Ballooning and individual necrotic keratinocytesprominentgranular layer, graft vs. host disease. Ballooning and http://www.thedoctorsdoctor.com/diseases/lichenoiddermatoses.htm

Background Lichenoid dermatoses and tissue reactions are some of the most diverse clinical and histologic presentations in dermatology and pathology. The term interface dermatitis is sometimes used interchangeably. The prototypical lichenoid dermatitis is lichen planus . Yet, there are numerous diseases that have similar histology. The following list describes some of them but many dermatoses have a lichenoid inflammatory cell component. Dermatomyositis Erythema multiforme Fixed drug eruptions Graft-versus-host disease ... Viral Exanthems Lichenoid tissue reactions are characterized by epidermal basal cell damage. Killer T lymphocytes (CD8) attack the basal keratinocytes probably induced by ICAM-1 (Intercellular adhesion molecule-1) expression in the keratinocytes. The result is cell death leading to Civatte bodies, a result of apoptosis . Vacuolar alteration, also known as liquefaction degeneration results form intracellular edema leading to separation. With continued damage at the dermoepidermal junction, melanin transfer from melanocytes to keratinocytes is disrupted leading to release and phagocytosis by macrophages. HISTOPATHOLOGICAL VARIANTS CHARACTERIZATION Lichenoid and granulomatous dermatitis.

54. ARIAD Pharmaceuticals half of the recipients of donor bone marrow and T cells, the T cells attack the patients'own tissues, causing a disease known as graftvs-host disease, or GvHD http://www.ariad.com/products/gvhd.html

55. Targeting The Signaling Molecule, LAT, For Preventing Graft-vs.-host Disease Targeting the signaling molecule, LAT, for preventing graftvs.-host disease . Funding Funding Leukemia Research Foundation. Principal Investigator http://www.surgery.wisc.edu/transplant/research/grant_mmh_lrf.shtml

"Targeting the signaling molecule, LAT, for preventing graft-vs.-host disease " Funding: Funding: Leukemia Research Foundation Principal Investigator: Majed M. Hamawy, Ph.D. Lab Website: (Lab website not available at this time) Project Summary: Administration Maps Affiliated Hospitals Med Student Information ... University of Wisconsin Department of Surgery First published: 07/15/02 Last updated : webmaster@surgery.wisc.edu

56. High-Dose Therapy And Stem Cell Transplantation seen substantial changes in the field of allogeneic and autologous stem cell transplantationincluding improvements in graftvs-host disease prevention and http://www.moffitt.usf.edu/pubs/ccj/v5n5/department1.html

High-Dose Therapy and Stem Cell Transplantation The use of high-dose therapy and stem cell transplantation for the treatment of both hematologic malignancies and solid tumors has increased dramatically over the past several years. A report from the International Bone Marrow Transplant Registry (IBMTR) and the Autologous Bone Marrow Transplant Registry (ABMTR) in 1997 described data available for more than 65,000 transplants, which represented about 40% of the allogeneic transplants performed worldwide since 1964 and approximately 50% of the autologous transplants performed in North and South America since 1989. The past several years have seen substantial changes in the field of allogeneic and autologous stem cell transplantation including improvements in graft-vs-host disease prevention and treatment, increased utilization of alternative donors, and a shift from the use of bone marrow to peripheral blood stem cells, especially in patients undergoing autologous stem cell transplantation. Stem cell transplantation has become standard therapy for several malignancies. One example is the use of allogeneic bone marrow transplantation for the treatment of leukemia and certain lymphomas. Yet, despite the broad application of this therapy, as well as the substantial improvements in clinical outcomes and treatment-related mortality, the use of high-dose therapy remains controversial for the treatment of certain malignancies, most notably breast cancer and other solid tumors. This edition of

57. Save On Health Books Concerning Graft Versus Host Disease Dermatology) Julian L. Verbov / Hardcover / Published 1987. graftvs.-hostDisease James LM Ferrara(editor), Et Al / Hardco Ver / Published 1996. http://www.healthlinkusa.com/bookpage/129_1.html

FREE. Would you like your site listed on HealthlinkUSA. Click here Today's Health Facts Find Drug Information ... Talk Health Tuesday April 08, 2003 Save on 1,000's of health books concerning 100's of different health topics! Graft Versus Host Disease Books Register here. It's Free! Be notified when there are updates to Graft Versus Host Disease books. Enter to Win a CD Player! To learn more about an individual book, or to make a purchase, just click on the title. Tell A Friend! Take a minute to tell a friend about HealthlinkUSA. Enter to Win a CD! Check all the Graft Versus Host Disease book pages for the largest selection. HealthlinkUSA site last updated: Tuesday April 08, 2003 Visit At Least Once A Week! We add new books regularly. Page 1 of 2 Next Immunobiology Of Bone Marrow Transplantation Graft-versus-host-disease (medical Intelligence Unit) Nelson J. Chao, Ph.d., M.d. Nelson J. Chao / Hardcover / Published 1998 Graft Versus Leukemia In Man And Animal Models Talking Points In Dermatology, I (new Clinical Applications. Dermatology) Julian L. Verbov / Hardcover / Published 1987 Graft-vs.-host Disease

58. Graft Vs graft vs. host disease. Home The vomiting infant Recurrent AbdominalPain in Childhood Hirschprung’s disease GASTROESOPHAGEAL http://gut1.peds.uiowa.edu/graft_vs.htm

Graft vs. Host disease Home The vomiting infant Recurrent Abdominal Pain in Childhood Hirschprung’s Disease ... Endoscopy photo index

59. Gale Encyclopedia Of Medicine: Graft-vs.-host Disease graftvs.-host disease. The only transplanted tissues that house enough immunecells to cause graft vs. host disease are the blood and the bone marrow. http://www.findarticles.com/cf_dls/g2601/0006/2601000605/p1/article.jhtml

Find Articles Home View By Subject View By Name Search Tips ... Help Search all magazines this magazine Arts/Entertain. Automotive Business/Fin. Comp./Tech. Health/Fitness Home/Family News/Society Reference/Ed. Sports for Search Tips : Use quotes to find a specific phrase, e.g. "Abe Lincoln" or "New York". Use the + sign for words that MUST be in the article, e.g. +Ford +SUV Terms related to this article: Anemia Antibiotics Chemotherapy Cortisone ... More links to Related Terms Buy and sell " " and millions of other items at eBay Gale Encyclopedia of Medicine Search this Magazine Go to Web site Print this article Email this article Page: Next Graft-vs.-host disease Author/s: J. Ricker Polsdorfer Definition Graft-vs.-host disease is an immune attack on the recipient by cells from a donor. Description The main problem with transplanting organs and tissues is that the recipient host does not recognize the new tissue as its own. Instead, it attacks it as foreign in the same way it attacks germs, to destroy it. If immunogenic cells from the donor are transplanted along with the organ or tissue, they will attack the host, causing graft vs. host disease. The only transplanted tissues that house enough immune cells to cause graft vs. host disease are the blood and the bone marrow. Blood transfusions are used every day in hospitals for many reasons. Bone marrow transplants are used to replace blood forming cells and immune cells. This is necessary for patients whose cancer treatment has destroyed their own bone marrow. Because bone marrow cells are among the most sensitive to radiation and chemotherapy, it often must be destroyed along with the cancer. This is true primarily of leukemias, but some other cancers have also been treated this way.

60. Cord Blood Registry - Expecting Parents FAQs: Cord Blood Stem Cells Less GVHD Overall, patients who receive cord blood transplants from a relativeexperience significantly less graft vs. host disease (GVHD), a transplant http://www.cordblood.com/expectingparents/faqs/cord_blood.asp

Call toll free: 1-888-CORD BLOOD About Cord Blood Banking Why Cbr Testimonials Common Misconceptions ... Site Map Expecting Parents:   FAQs Cord Blood Stem Cells Banking Cord Blood Stem Cells Collecting Cord Blood Stem Cells Shipping and Handling Cord Blood Processing and Banking of Cord Blood ... Enrolling with Cbr Cord Blood Stem Cells What is cord blood? What are stem cells? How are stem cells used? What types of diseases are treated with stem cell transplantation? ... What is HLA-matching? What is cord blood? Cord blood, which is also called "placental blood," is the blood that remains in the umbilical cord and placenta following birth and after the cord is cut. Cord blood is routinely discarded with the placenta and umbilical cord. Your baby's umbilical cord blood is a valuable source of stem cells, which are genetically unique to your baby and family. Return to Index What are stem cells? Stem cells are the body's "master" cells because they create all other tissues, organs, and systems in the body. The stem cells found in cord blood are the building blocks of your blood and immune system and most readily reproduce into: Red Blood Cells - which carry oxygen to all the cells in the body White Blood Cells - which fight infection Platelets - which aid in clotting in the event of injury There are three sources where stem cells are commonly found, they are:

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-60 of 92    Back | 1  | 2  | 3  | 4  | 5  | Next 20